TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis.
TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis.
复制标题
DOI：
10.3892/mco.2016.1057
复制
发表时间：
2016-12
影响因子：
1.2
通讯作者：
Liu B
中科院分区：
文献类型：
--
作者：
Gu J;Zhou Y;Huang L;Ou W;Wu J;Li S;Xu J;Feng J;Liu B
许多研究已经检查了肿瘤蛋白53（TP 53）突变与非小细胞肺癌（NSCLC）患者临床结局之间的相关性，尽管这些研究产生了相互矛盾的结果。在本研究中，检索了更新至2015年9月的电子数据库，以查找相关研究。对符合条件的研究进行荟萃分析，定量评价TP 53突变与NSCLC患者生存期之间的相关性。进行亚组和敏感性分析。共纳入了19项研究，共涉及6，084例NSCLC患者。当将TP 53突变组（n= 1，406）与野生型组（缺乏TP 53突变; n= 1，965）进行比较时，野生型组的总生存率显着更高[风险比（HR），1.26; 95%置信区间（CI）1.12-1.41，P<0.0001]。在包括早期NSCLC患者（包括I/II期）的亚组中，发现野生型组的总生存期显著获益（HR，1.93，95% CI，1.17-3.19，P=0.01;异质性，I2= 0.0%，P=0.976）和腺癌患者（HR，3.06; 95% CI，1.66-5.62，P<0.0001;异质性：I2= 0.0%，P=0.976）。这项荟萃分析表明，TP 53基因变异可能是NSCLC患者预后不良的指标。此外，研究结果还表明，TP 53突变的作用可能会根据不同的病理类型和临床分期而有所不同。这些突变的存在可以定义适合研究性治疗策略的NSCLC患者亚组。
A number of studies have examined the association between tumor protein 53 (TP53) mutations and the clinical outcome in patients with non-small-cell lung cancer (NSCLC), although these have yielded conflicting results. In the present study, electronic databases updated to September 2015 were searched to find relevant studies. A meta-analysis was performed on the eligible studies, which quantitatively evaluated the association between the TP53 mutations and the survival of patients with NSCLC. Subgroup and sensitivity analyses were performed. A total of 19 studies that involved a total of 6,084 patients with NSCLC were included. When the TP53 mutation group (n=1,406) was compared with the wild-type group (lacking TP53 mutations; n=1,965), the wild-type group was associated with a significantly higher overall survival rate [hazard ratio (HR), 1.26; 95% confidence interval (CI) 1.12–1.41, P<0.0001]. Significant benefits of overall survival in the wild-type group were found in the subgroup involving patients with NSCLC in the early stages, including the I/II phases (HR, 1.93, 95% CI, 1.17–3.19, P=0.01; heterogeneity, I2=0.0%, P=0.976) and patients with adenocarcinoma (HR, 3.06; 95% CI, 1.66–5.62, P<0.0001; heterogeneity: I2=0.0%, P=0.976). This meta-analysis has indicated that TP53 gene alteration may be an indicator of a poor prognosis in patients with NSCLC. Furthermore, the results also suggested that the role of TP53 mutations may differ according to different pathological types and clinical stages. The presence of these mutations may define a subset of patients with NSCLC appropriate for investigational therapeutic strategies.